menu
    • menu

    Company profile for Fareva

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-21

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-14

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Fareva’s API division has special technologies for high potent APIs (HPAPIs) down to the OEB-6 level, aseptic crystallization (sterile APIs), Spray Drying etc, with volumes ranging from a few kgs to multi tons production.
    Fareva’s Drug Product division offers different technologies: injectables (lyophilized, solution, suspension, vial, ampoules, pre-filled syringes), unidoses and multidoses BFS, solids (tablets, hard ...
    Fareva’s API division has special technologies for high potent APIs (HPAPIs) down to the OEB-6 level, aseptic crystallization (sterile APIs), Spray Drying etc, with volumes ranging from a few kgs to multi tons production.
    Fareva’s Drug Product division offers different technologies: injectables (lyophilized, solution, suspension, vial, ampoules, pre-filled syringes), unidoses and multidoses BFS, solids (tablets, hard capsules, powders), semi-solids (cream, gel suppositories) and liquids (oral and external, sprays, aerosols).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    FarevaLuxembourg Flag
    Country
    Country
    Luxembourg
    Address
    Address
    28 place de la gare, 1616 Luxembourg
    Telephone
    Telephone
    +49 16090545489
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.fareva.com/en
    Linkedin
    Linkedin
    https://www.linkedin.com/company/fareva
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI North America

    Not Confirmed

    envelop Contact Supplier

    CPhI North America

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “Our unmatched efficiency and track record of faster DMF filings give our customers a critical competitive advantage”

    “Our unmatched efficiency and track record of faster DMF filings give our customers a critical competitive advantage”

    This week, SpeakPharma interviews Pete Werth III, the new president of ChemWerth, a company that has been at the forefront of the generic pharmaceutical industry for over four decades. He shares his vision for ChemWerth, which includes his commitment to strengthening global manufacturing relationships, and enhancing supply chain resilience. Additionally, he highlights the key aspects of a successful drug master file (DMF). HIGHLIGHTS// Pete Werth III, the new president of ChemWerth/ vision for ChemWerth/ commitment to strengthening global manufacturing relationships/ key aspects of a successful drug master file Your father, Peter J. Werth, is recognized as one of the founders of the generic pharmaceutical industry, having built ChemWerth from the ground up over four decades ago. How do you view his legacy? As you take the helm, what key lessons or principles from his leadership do you intend to carry forward? My father, Peter J. Werth, is a true pioneer in the generic pharmaceutical industry. Over his 42‐year tenure, he not only built ChemWerth from a humble garage startup into a global leader in generic API development but also established standards that many in our industry now take for granted. Under his leadership, we filed our very first DMF in 1987 and have since achieved more than 500 DMF filings. With an average review cycle of just 0.79, we have been far outperforming the industry average of 2.5 cycles. His focus on quality, regulatory excellence, and a relentless commitment to customers’ success set the foundation for our reputation as a trusted supplier of over 500 APIs sourced from more than 30 cGMP-certified facilities worldwide. Equally inspiring is his dedication to nurture long-term, mutually beneficial relationships with manufacturing partners across the US, Europe, India, and China, as well as his passion for giving back to the community through philanthropic initiatives. As I take the helm, I intend to build on his guiding principles — sustaining our high standards of quality and compliance while pursuing innovation in regulatory strategy, diversifying our supply chain, and embracing new technologies and approaches to remain competitive in an evolving market. I will also strive to continue his legacy of mentorship, ensuring that our company culture remains rooted in integrity and diligence, with an unyielding focus on making safe, affordable medicines available worldwide. HIGHLIGHTS// trusted supplier of over 500 APIs/ 30 cGMP-certified facilities worldwide/ embracing new technologies and approaches to remain competitive What are your top priorities as the new president of ChemWerth? How do you plan to strengthen and expand relationships with manufacturers worldwide? My immediate priorities as the new president are twofold: to enhance the value we deliver to our customers and, to deepen our relationships with our manufacturing partners worldwide. We will further diversify our supply chain and broaden our product portfolio. Our expansion plans include upgrading equipment, and hiring additional highly skilled scientists, engineers, and GMP auditors. We will also leverage our proprietary product selection and regulatory submission processes. These processes help us get the regulatory filing right the first time, and allows us to be approved 44 percent faster than the industry average. This helps our customers gain a competitive edge in the market. In essence, by strengthening operational excellence and expanding our global network, we intend to continue the company’s long-standing commitment to customer success and process innovation. We plan to reinforce our long-standing relationships with our manufacturers — especially those in strategic markets like China and India — by helping our partners meet the highest standards of regulatory compliance and current good manufacturing practice (cGMP) quality. This balanced approach of strengthening existing partnerships while pioneering new ones is key to maintaining and growing our competitive edge. HIGHLIGHTS// diversify our supply chain and broaden our product portfolio/ commitment to customer success and process innovation/ filings approved 44 percent faster than the industry average When ChemWerth last spoke to PharmaCompass, there was a mention of investing millions of dollars in expanding manufacturing partnerships in China and India. Can you elaborate on the success of these partnerships, and how have they contributed to ChemWerth’s overall growth? Our strategic, multimillion-dollar investments in manufacturing partnerships are a cornerstone of our growth strategy. Over the past few years, these joint ventures have proven their worth by diversifying our supply base and mitigating the risk of global supply chain disruptions — a lesson that became all too clear during the Covid-19 pandemic. These investments are already paying dividends. They help us support manufacturers producing steroids, hormones, veterinary products, and large-volume APIs, while also accelerating the development of small-molecule inhibitors and new generic APIs. We have ensured that our partners are equipped with the latest equipment and trained personnel to meet cGMP standards. By partnering with facilities in these markets, we now have access to state-of-the-art production capabilities that enable us to produce a wider range of APIs at competitive costs. The success of these partnerships is evident in our ability to consistently file DMFs rapidly — often on the first cycle — and deliver affordable, high-quality medicines to patients worldwide. This supports our clients’ growth trajectory and has helped us expand into new markets. This strategy has reinforced our global footprint — supporting our presence in 38 countries with over 100 products — and positioned us well to capitalize on a global generic drug market projected to grow at a compounded annual growth rate of 5.4 percent from 2022 to 2030, to reach a size of US$ 671 billion by 2030. HIGHLIGHTS// strategic multimillion-dollar investments/ support manufacturers producing steroid, hormone, veterinary products/ development of small-molecule inhibitors and new generic APIs/ ensured partners are equipped with the latest equipment and trained personnel ChemWerth has an impressive track record, and an over 40-year relationship with the US Food and Drug Administration (FDA). What are the key aspects of a successful DMF? Are there specific challenges manufacturers face in preparing DMFs, and how does ChemWerth help them overcome these hurdles? ChemWerth’s record of filing over 500 DMFs in 38 countries reflects our commitment to excellence in regulatory compliance and quality management. A successful DMF is built on comprehensive documentation that rigorously follows cGMP guidelines, robust analytical validation, and detailed tracking of every step. Every DMF we file meticulously details the entire manufacturing process — from raw material acquisition to final batch production. This comprehensive approach ensures that our submissions meet the rigorous quality, safety, and efficacy standards expected by the FDA. Our team stays continuously updated on the evolving guidelines and protocols, which allows us to file DMFs that align with current FDA practices. We recognize that many manufacturers face challenges such as complex regulatory requirements, lengthy review cycles, and the need for precise coordination between various production stages. ChemWerth helps them overcome these hurdles by offering end-to-end regulatory support, detailed internal audits, and continuous training on cGMP and FDA requirements. Our efficiency is a critical competitive advantage. By receiving approvals 44 percent faster than the industry average, we help our customers get their products to market faster, resulting in larger market share and increased profits. HIGHLIGHTS// over 500 DMFs in 38 countries/ robust analytical validation/ end-to-end regulatory support What is your vision for ChemWerth over the next few years? How do you plan to navigate the challenges and opportunities in the generic pharmaceutical industry? I plan to continue to add value for our customers, and look for innovative ways to compete in today’s generic pharmaceutical landscape. At ChemWerth, our vision for the future is rooted in both our proud legacy and our relentless drive for innovation. We will further diversify our supply chain and expand our product portfolio. We have begun leveraging our expertise to supply APIs for biosimilars and new drug applications (NDAs), while maintaining our reputation for rapid regulatory approvals. With unwavering determination, we uphold our “First to Quality. Fast to Market.” approach — delivering high-quality APIs to customers worldwide while leveraging our expertise to give them a competitive edge in their markets. HIGHLIGHTS// supply APIs for biosimilars and NDAs/ give customers a competitive edge in their markets 

    Impressions: 955

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage

    Radio Compass
    12 Mar 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    Top Pharma Companies & Drugs in 2024: Merck’s Keytruda maintains top spot as Novo’s semaglutide nips at its heels

    Top Pharma Companies & Drugs in 2024: Merck’s Keytruda maintains top spot as Novo’s semaglutide nips at its heels

    In 2024, Big Pharma players consolidated and maintained their dominance, even as innovation continued to reshape the pharmaceutical landscape. The primary change last year was the meteoric rise of glucagon-like peptide-1 (GLP-1) receptor agonists that treat diabetes and help in weight loss.Amongst drugmakers, Pfizer retained its numero uno spot with an impressive US$ 63.6 billion in prescription drug sales (up 7 percent from US$ 59.56 billion reported in 2023), despite ever-shrinking Comirnaty sales, which settled at US$ 5.35 billion in 2024 (from US$ 11.22 billion in 2023).Merck secured the second position with revenues of US$ 57.4 billion, a growth of 7 percent over 2023. This performance was predominantly fueled by Keytruda, which now accounts for more than half of Merck’s total pharmaceutical revenue. Johnson & Johnson came a close third with US$ 57 billion in prescription drug sales (up from US$ 54.76 billion in 2023).AbbVie held the fourth position with US$ 56.33 billion in sales, achieving 3.7 percent growth despite the ongoing erosion of Humira revenue. This flagship immunology drug saw sales plummet 37.6 percent to approximately US$ 9 billion, a US$ 5.4 billion reduction compared to 2023. Humira’s loss was offset by AbbVie’s newer immunology assets, particularly Skyrizi and Rinvoq, both of which demonstrated exceptional growth trajectories. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available)European giants Astra, Roche, Novartis, Sanofi round out top 10 list; Novo, Lilly see astounding growthWhile the top four positions were dominated by American drugmakers, European giants dominated the lower half of the top 10 list.AstraZeneca secured the fifth spot with US$ 54.1 billion in sales, thereby posting impressive growth of 18.1 percent over 2023. Roche claimed the sixth position with US$ 50.9 billion in sales while Novartis ranked seventh — with sales of US$ 50.3 billion. Novartis' impressive 10.8 percent sales growth is attributed to its innovative medicines portfolio. Oncology therapies remained a cornerstone for both these Swiss drugmakers.Bristol Myers Squibb (BMS) secured eighth position with revenues of US$ 48.3 billion, representing 7.3 percent growth over the previous year. At US$ 45 billion, Eli Lilly posted 32 percent revenue growth last year. Its GLP-1 drug Mounjaro helped Lilly move up from the tenth in 2023 to the ninth spot last year.Sanofi landed the tenth position with US$ 42.6 billion in sales, propelled largely by the expanding indications of Dupixent. The French multinational has increasingly focused on this immunology blockbuster, while also garnering more sales from its vaccine and rare disease portfolios.Novo Nordisk merits a mention as it posted an incredible 26 percent year-on-year growth. It retained its eleventh spot with US$ 40.25 billion in sales. Novo’s growth was driven almost exclusively by the extraordinary success of its GLP-1 receptor agonist portfolio. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available)       Merck’s Keytruda retains throne with US$ 29.5 bn in sales, as Novo’s semaglutide nips at its heelsMoving on to drugs, Merck’s Keytruda (pembrolizumab) solidified its position as the world’s top-selling pharmaceutical product with sales exceeding US$ 29.5 billion and year-on-year growth of 17.88 percent (US$ 4.5 billion). This remarkable performance was driven by steady sales growth across more than 40 indications in the US. In 2024 alone, Keytruda secured four new approvals from the US Food and Drug Administration (FDA).However, Novo Nordisk’s semaglutide sales (Ozempic, Wegovy and Rybelsus) gave Keytruda a run for its money. Across the three blockbuster drugs, semaglutide earned the Danish drugmaker around US$ 28 billion — i.e. a year-on-year increase of 38 percent.Novo’s Ozempic (semaglutide) reached over US$ 16.7 billion in sales — a 20 percent increase from 2023. Originally approved in 2017 to improve glycemic control, Ozempic bagged additional approvals in 2020, and in January 2025. It is now approved to reduce the risk of major cardiovascular events, as well as to reduce cardiovascular risk and to lower the likelihood of chronic kidney disease in type 2 diabetes patients.Sales of Wegovy (semaglutide), the other blockbuster GLP-1 drug from Novo, grew by a whopping 85.7 percent to over US$ 8 billion.Sanofi and Regeneron’s Dupixent (dupilumab) secured the number three spot with sales of US$ 13.6 billion, representing an impressive 17.2 percent year-on-year growth. In 2024, Dupixent received three new approvals and one label update. Notably, it became the first-ever biologic medicine approved for patients with chronic obstructive pulmonary disease (COPD). View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available) AbbVie’s post-Humira strategy pays off as Skyrizi surges 51%; Lilly’s Mounjaro posts 124% growthGilead Sciences’ HIV treatment Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) showed robust growth of 13.27 percent, touching sales of US$ 13.42 billion in 2024 and emerging as the fourth largest selling drug. Biktarvy now commands over 50 percent of the US HIV treatment market. Unlike many other drugs on this list, Biktarvy faces no immediate patent challenges, with key protections expected to remain intact until 2033.BMS and Pfizer’s anticoagulant Eliquis (apixaban) claimed the fifth position with US$ 13.33 billion in sales, representing a 9.21 percent year-on-year increase. AbbVie’s Skyrizi (risankizumab) emerged as one of the fastest-growing assets with a 50.95 percent year-on-year increase, generating US$ 11.71 billion in 2024 sales, thereby surpassing Humira’s (adalimumab) diminished sales.This impressive performance, combined with Rinvoq’s (upadacitinib) growth, has prompted  AbbVie to raise its long-term outlook for these products. The company now expects combined Skyrizi and Rinvoq revenues to exceed US$ 31 billion by 2027, with Skyrizi alone projected to generate over US$ 20 billion.Johnson & Johnson’s Darzalex (daratumumab) claimed the seventh position with US$ 11.67 billion in sales, representing 19.77 percent growth over 2023.Lilly’s Mounjaro (tirzepatide) demonstrated dramatic growth with sales increasing 123.51 percent to US$ 11.54 billion. This performance was complemented by Zepbound (tirzepatide, for weight loss), which contributed US$ 4.9 billion to Lilly’s revenue. By the end of 2024, Mounjaro received FDA approval for a new indication in obstructive sleep apnea (OSA), becoming the first and only prescription medicine for moderate-to-severe OSA in adults with obesity.Stelara (ustekinumab) ranked ninth, bringing J&J sales of US$ 10.36 billion, showing a modest decline of 4.91 percent from its 2023 sales.Vertex’s triple-combination therapy Trikafta (elexacaftor/tezacaftor/ivacaftor) for treating cystic fibrosis rounded out the top ten list with sales of US$ 10.2 billion, up 14 percent from the previous year. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available) Our viewIn 2024, transformative therapies like GLP-1 receptor agonists drove growth in the pharmaceutical industry. This year, we expect GLP-1 drugs to dethrone Keytruda from the number one spot. Along with novel immunology agents, we expect GLP-1 drugs to realign the pharmaceutical market.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 2173

    https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels

    #PharmaFlow by PHARMACOMPASS
    24 Apr 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Strategic Investments to Meet the Growing Demand for Sterile
    Strategic Investments to Meet the Growing Demand for Sterile

    12 Nov 2024

    // PRESS RELEASE

    https://www.fareva.com/en/news/fareva-strategic-investments-to-meet-the-growing-demand-for-sterile-pharmaceutical-products

    PRESS RELEASE
    12 Nov 2024
    Share Share
    Our next beauty 2024 exhibitions
    Our next beauty 2024 exhibitions

    13 Aug 2024

    // PRESS RELEASE

    https://www.fareva.com/en/news/our-next-beauty-2024-exhibitions

    PRESS RELEASE
    13 Aug 2024
    Share Share
    Fareva and ApiJect Sign a Licensing Agreement
    Fareva and ApiJect Sign a Licensing Agreement

    10 Dec 2021

    // PRESS RELEASE

    https://apiject.com/press-announcements/fareva-and-apiject-sign-a-licensing-agreement-to-create-a-france-based-500m-unit-annual-capacity-for-single-dose-prefilled-vaccine-injections/

    PRESS RELEASE
    10 Dec 2021
    Share Share
    Fareva, ApiJect Sign 10-Year Blow-Fill-Seal Licensing Agreement
    Fareva, ApiJect Sign 10-Year Blow-Fill-Seal Licensing Agreement

    10 Dec 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/fareva-and-apiject-sign-a-licensing-agreement-to-create-a-france-based-500m-unit-annual-capacity-for-single-dose-prefilled-vaccine-injections-301441485.html

    PRNEWSWIRE
    10 Dec 2021
    Share Share
    Fareva Excella increases its production capacities of highly active products
    Fareva Excella increases its production capacities of highly active products

    11 May 2021

    // PRESS RELEASE

    https://www.fareva.com/en/news/fareva-excella-augmente-ses-capacites-de-production-de-produits-hautement-actifs

    PRESS RELEASE
    11 May 2021
    Share Share
    Fareva takes over Novartis location with Wolf Theiss
    Fareva takes over Novartis location with Wolf Theiss

    28 Apr 2021

    // EXTRAJOURNALS

    https://extrajournal.net/2021/04/28/fareva-uebernimmt-novartis-standort-mit-wolf-theiss/

    EXTRAJOURNALS
    28 Apr 2021
    Share Share

    ALL APIs

    read-moreClick the button for full data set
    read-moreClick the button for full data set

    01

    Anastrozole

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AACR Annual meeting
    Not Confirmed
    arrow

    Anastrozole

    Luxembourg

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down Click Us! arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2017-04-21

    Pay. Date : 2015-08-10

    DMF Number : 20338

    Submission : 2007-03-09

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2024-160 - Rev 00

    Issue Date : 2024-08-30

    Type : Chemical

    Substance Number : 2406

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 222MF10240

    Registrant's Address : NUERNBERGER STRASSE 12, 90537 FEUCHT, GERMANY

    Initial Date of Registration : 2010-10-13

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 46014-1160

    Start Marketing Date : 2021-05-12

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF arrow-down
    ✖

    Registrant Name : Samoh Pharmaceutical Co., Ltd.

    Registration Date : 2022-10-21

    Registration Number : 20221021-209-J-1387

    Manufacturer Name : Excella GmbH & Co. KG

    Manufacturer Address : Nurnberger Strasse 12, 90537 Feucht, Germany

     VMF CN arrow-down
    ✖
    Available Reg. Filing : CN
    AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Bicalutamide

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AACR Annual meeting
    Not Confirmed
    arrow

    Bicalutamide

    Luxembourg

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2015-08-19

    Pay. Date : 2015-08-10

    DMF Number : 21863

    Submission : 2008-08-04

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2012-270 - Rev 03

    Issue Date : 2024-10-25

    Type : Chemical

    Substance Number : 2196

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 220MF10252

    Registrant's Address : NUERNBERGER STRASSE 12, 90537 FEUCHT, GERMANY

    Initial Date of Registration : 2008-12-12

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 46014-1163

    Start Marketing Date : 2013-05-02

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT FOR ...

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Doxazosin Mesylate

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AACR Annual meeting
    Not Confirmed
    arrow

    Doxazosin Mesylate

    Luxembourg

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2013-04-15

    Pay. Date : 2013-01-08

    DMF Number : 12634

    Submission : 1997-08-27

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2008-328 - Rev 02

    Issue Date : 2021-06-09

    Type : Chemical

    Substance Number : 2125

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 218MF10433

    Registrant's Address : NUERNBERGER STRASSE 12, 90537 FEUCHT, GERMANY

    Initial Date of Registration : 2006-04-27

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 46014-1001

    Start Marketing Date : 1997-10-01

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT FOR ...

    KDMF arrow-down
    ✖

    Registrant Name : Samoh Pharmaceutical Co., Ltd.

    Registration Date : 2005-08-31

    Registration Number : 20050831-14-B-58-02

    Manufacturer Name : Excella GmbH & Co. KG

    Manufacturer Address : Nurnberger Str. 12 90537 Feucht, Germany (Sudwestpark 50 90449 Nurnberg, Germany)

     VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Estradiol

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AACR Annual meeting
    Not Confirmed
    arrow

    Estradiol

    Luxembourg

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2014-10-27

    Pay. Date : 2014-04-24

    DMF Number : 22972

    Submission : 2009-07-21

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2009-241 - Rev 06

    Issue Date : 2023-09-20

    Type : Chemical

    Substance Number : 821

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 303MF10123

    Registrant's Address : Parc Industriel d'Incarville Parc de la Fringale CS 10606 27106 Val de Reuil Cedex France

    Initial Date of Registration : 2021-08-02

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 24823-904

    Start Marketing Date : 2012-07-10

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Estradiol Valerate

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AACR Annual meeting
    Not Confirmed
    arrow

    Estradiol Valerate

    Luxembourg

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2017-06-02

    Pay. Date : 2017-04-04

    DMF Number : 23948

    Submission : 2010-07-02

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2010-224 - Rev 05

    Issue Date : 2024-06-20

    Type : Chemical

    Substance Number : 1614

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 303MF10163

    Registrant's Address : Parc Industriel d'Incarville Parc de la Fringale CS 10606 27106 Val de Reuil Cedex France

    Initial Date of Registration : 2021-11-10

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 24823-906

    Start Marketing Date : 2011-04-07

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Methotrexate

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AACR Annual meeting
    Not Confirmed
    arrow

    Methotrexate

    Luxembourg

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2013-10-04

    Pay. Date : 2013-09-26

    DMF Number : 11704

    Submission : 1995-10-05

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2000-024 - Rev 10

    Issue Date : 2020-02-21

    Type : Chemical

    Substance Number : 560

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 219MF10360

    Registrant's Address : NUERNBERGER STRASSE 12, 90537 FEUCHT, GERMANY

    Initial Date of Registration : 2007-12-13

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 46014-1133

    Start Marketing Date : 2017-11-29

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF ASMF, CN arrow-down
    ✖
    Available Reg. Filing : ASMF, CN
    AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Norethisterone Acetate

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AACR Annual meeting
    Not Confirmed
    arrow

    Norethisterone Acetate

    Luxembourg

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2014-06-02

    Pay. Date : 2013-09-18

    DMF Number : 24913

    Submission : 2011-05-25

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2011-242 - Rev 02

    Issue Date : 2023-04-03

    Type : Chemical

    Substance Number : 850

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 230MF10159

    Registrant's Address : Parc Industriel d'Incarville Parc de la Fringale CS 10606 27106 Val de Reuil Cedex France

    Initial Date of Registration : 2018-11-28

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 24823-909

    Start Marketing Date : 2011-09-21

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Tamoxifen Citrate

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AACR Annual meeting
    Not Confirmed
    arrow

    Tamoxifen Citrate

    Luxembourg

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2013-10-04

    Pay. Date : 2013-09-26

    DMF Number : 5204

    Submission : 1983-12-22

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 1996-098 - Rev 09

    Issue Date : 2020-03-11

    Type : Chemical

    Substance Number : 1046

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 219MF10242

    Registrant's Address : NUERNBERGER STRASSE 12, 90537 FEUCHT, GERMANY

    Initial Date of Registration : 2007-07-17

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 46014-1180

    Start Marketing Date : 2022-01-03

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF arrow-down
    ✖

    Registrant Name : Samoh Pharmaceutical Co., Ltd.

    Registration Date : 2021-06-14

    Registration Number : 20210614-209-J-893

    Manufacturer Name : Excella GmbH & Co. KG

    Manufacturer Address : Nürnberger Str. 12, 90537 Feucht, Germany

     VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Temozolomide

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AACR Annual meeting
    Not Confirmed
    arrow

    Temozolomide

    Luxembourg

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2015-02-25

    Pay. Date : 2013-09-26

    DMF Number : 26032

    Submission : 2012-08-16

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2018-246 - Rev 03

    Issue Date : 2024-04-12

    Type : Chemical

    Substance Number : 2780

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 302MF10046

    Registrant's Address : NUERNBERGER STRASSE 12, 90537 FEUCHT, GERMANY

    Initial Date of Registration : 2020-04-17

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 46014-1460

    Start Marketing Date : 2024-01-01

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Timolol Maleate

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AACR Annual meeting
    Not Confirmed
    arrow

    Timolol Maleate

    Luxembourg

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2013-10-05

    Pay. Date : 2013-09-26

    DMF Number : 15516

    Submission : 2001-07-04

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2001-296 - Rev 05

    Issue Date : 2023-07-05

    Type : Chemical

    Substance Number : 572

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 219MF10207

    Registrant's Address : NUERNBERGER STRASSE 12, 90537 FEUCHT, GERMANY

    Initial Date of Registration : 2007-06-13

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 46014-1059

    Start Marketing Date : 2007-08-02

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT FOR ...

    KDMF arrow-down
    ✖

    Registrant Name : Samoh Pharmaceutical Co., Ltd.

    Registration Date : 2012-12-27

    Registration Number : 20121227-201-I-91-04

    Manufacturer Name : Fareva La Vallee

    Manufacturer Address : Zone Industrielle de Blavozy, 928 avenue Lavoisier, 43700 Saint-Germain-Laprade

     VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    USDMF

    read-more
    read-more

    01

    Acyclovir Sodium

    Luxembourg
    AACR Annual meeting
    Not Confirmed
    arrow

    02

    Anastrozole

    Luxembourg
    AACR Annual meeting
    Not Confirmed
    arrow

    03

    Baclofen

    Luxembourg
    AACR Annual meeting
    Not Confirmed
    arrow

    04

    Bicalutamide Milled Z

    Luxembourg
    AACR Annual meeting
    Not Confirmed
    arrow

    05

    Bupivacaine Hydrochloride

    Luxembourg
    AACR Annual meeting
    Not Confirmed
    arrow

    06

    Buspirone Hydrochloride

    Luxembourg
    AACR Annual meeting
    Not Confirmed
    arrow

    07

    Busulfan

    Luxembourg
    AACR Annual meeting
    Not Confirmed
    arrow

    08

    Cevimeline Hydrochloride

    Luxembourg
    AACR Annual meeting
    Not Confirmed
    arrow

    09

    Deferoxamine Mesylate

    Luxembourg
    AACR Annual meeting
    Not Confirmed
    arrow

    10

    Deferoxamine Mesylate Usp

    Luxembourg
    AACR Annual meeting
    Not Confirmed
    arrow
    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    CEP/COS

    read-more
    read-more

    01

    Anastrozole, Micronised (Z), milled and ...

    CEP/COS

    AACR Annual meeting
    Not Confirmed
    arrow

    02

    Anastrozole, Milled and micronised (Z); ...

    CEP/COS

    AACR Annual meeting
    Not Confirmed
    arrow

    03

    Bicalutamide, Milled, Milled (Z)

    CEP/COS

    AACR Annual meeting
    Not Confirmed
    arrow

    04

    Bupivacaine hydrochloride

    CEP/COS

    AACR Annual meeting
    Not Confirmed
    arrow

    05

    Busulfan

    CEP/COS

    AACR Annual meeting
    Not Confirmed
    arrow

    06

    Doxazosin mesilate

    CEP/COS

    AACR Annual meeting
    Not Confirmed
    arrow

    07

    Estradiol hemihydrate, Micronised fine, ...

    CEP/COS

    AACR Annual meeting
    Not Confirmed
    arrow

    08

    Estradiol valerate, Micronised fine, non...

    CEP/COS

    AACR Annual meeting
    Not Confirmed
    arrow

    09

    Levothyroxine sodium

    CEP/COS

    AACR Annual meeting
    Not Confirmed
    arrow

    10

    Methotrexate

    CEP/COS

    AACR Annual meeting
    Not Confirmed
    arrow
    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    JDMF

    read-more
    read-more

    01

    Anastrozole

    JDMF

    AACR Annual meeting
    Not Confirmed
    arrow

    Anastrozole

    Luxembourg
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Luxembourg
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Fareva

    Registration Number : 222MF10240

    Registrant's Address : NUERNBERGER STRASSE 12, 90537 FEUCHT, GERMANY

    Initial Date of Registration : 2010-10-13

    Latest Date of Registration : 2018-08-08

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Baclofen

    JDMF

    AACR Annual meeting
    Not Confirmed
    arrow

    Baclofen

    Luxembourg
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Luxembourg
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Fareva

    Registration Number : 220MF10253

    Registrant's Address : NUERNBERGER STRASSE 12, 90537 FEUCHT, GERMANY

    Initial Date of Registration : 2008-12-12

    Latest Date of Registration : 2008-12-12

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Bicalutamide

    JDMF

    AACR Annual meeting
    Not Confirmed
    arrow

    Bicalutamide

    Luxembourg
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Luxembourg
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Fareva

    Registration Number : 220MF10252

    Registrant's Address : NUERNBERGER STRASSE 12, 90537 FEUCHT, GERMANY

    Initial Date of Registration : 2008-12-12

    Latest Date of Registration : 2021-10-27

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Deferoxamine mesylate

    JDMF

    AACR Annual meeting
    Not Confirmed
    arrow

    05

    Doxazosin mesylate

    JDMF

    AACR Annual meeting
    Not Confirmed
    arrow

    Doxazosin mesylate

    Luxembourg
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Luxembourg
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Fareva

    Registration Number : 218MF10433

    Registrant's Address : NUERNBERGER STRASSE 12, 90537 FEUCHT, GERMANY

    Initial Date of Registration : 2006-04-27

    Latest Date of Registration : 2007-06-18

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Estradiol hydrate

    JDMF

    AACR Annual meeting
    Not Confirmed
    arrow

    Estradiol hydrate

    Luxembourg
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Luxembourg
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Fareva

    Registration Number : 303MF10123

    Registrant's Address : Parc Industriel d'Incarville Parc de la Fringale CS 10606 27106 Val de Reuil Cedex Fr...

    Initial Date of Registration : 2021-08-02

    Latest Date of Registration : 2021-08-02

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Estradiol Valerate

    JDMF

    AACR Annual meeting
    Not Confirmed
    arrow

    Estradiol Valerate

    Luxembourg
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Luxembourg
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Fareva

    Registration Number : 303MF10163

    Registrant's Address : Parc Industriel d'Incarville Parc de la Fringale CS 10606 27106 Val de Reuil Cedex Fr...

    Initial Date of Registration : 2021-11-10

    Latest Date of Registration : 2022-09-14

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Ganciclovir

    JDMF

    AACR Annual meeting
    Not Confirmed
    arrow

    Ganciclovir

    Luxembourg
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Luxembourg
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Fareva

    Registration Number : 222MF10281

    Registrant's Address : NUERNBERGER STRASSE 12, 90537 FEUCHT, GERMANY

    Initial Date of Registration : 2010-12-24

    Latest Date of Registration : 2023-11-01

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Haloperidol

    JDMF

    AACR Annual meeting
    Not Confirmed
    arrow

    Haloperidol

    Luxembourg
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Luxembourg
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Fareva

    Registration Number : 221MF10041

    Registrant's Address : NUERNBERGER STRASSE 12, 90537 FEUCHT, GERMANY

    Initial Date of Registration : 2009-02-23

    Latest Date of Registration : 2021-11-02

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Methotrexate

    JDMF

    AACR Annual meeting
    Not Confirmed
    arrow

    Methotrexate

    Luxembourg
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Luxembourg
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Fareva

    Registration Number : 219MF10360

    Registrant's Address : NUERNBERGER STRASSE 12, 90537 FEUCHT, GERMANY

    Initial Date of Registration : 2007-12-13

    Latest Date of Registration : 2024-11-27

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Services

    Upload your portfolio for free, ask us

    Packaging

    Click here to discover the service providers for Packaging

    API Manufacturing

    Click here to discover the service providers for API Manufacturing

    Drug Product Manufacturing

    Click here to discover the service providers for Drug Product Manufacturing

    API & Drug Product Development

    Click here to discover the service providers for API & Drug Product Development

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Fareva and get a quotation

    Fareva is a supplier offers 68 products (APIs, Excipients or Intermediates).

    Find a price of Anastrozole bulk with DMF, CEP, JDMF offered by Fareva

    Find a price of Bicalutamide bulk with DMF, CEP, JDMF offered by Fareva

    Find a price of Doxazosin Mesylate bulk with DMF, CEP, JDMF offered by Fareva

    Find a price of Estradiol bulk with DMF, CEP, JDMF offered by Fareva

    Find a price of Estradiol Valerate bulk with DMF, CEP, JDMF offered by Fareva

    Find a price of Methotrexate bulk with DMF, CEP, JDMF offered by Fareva

    Find a price of Norethisterone Acetate bulk with DMF, CEP, JDMF offered by Fareva

    Find a price of Tamoxifen Citrate bulk with DMF, CEP, JDMF offered by Fareva

    Find a price of Temozolomide bulk with DMF, CEP, JDMF offered by Fareva

    Find a price of Timolol Maleate bulk with DMF, CEP, JDMF offered by Fareva

    Find a price of Baclofen bulk with DMF, JDMF offered by Fareva

    Find a price of Bupivacaine Hydrochloride bulk with DMF, CEP offered by Fareva

    Find a price of Busulfan bulk with DMF, CEP offered by Fareva

    Find a price of Deferoxamine Mesylate bulk with DMF, JDMF offered by Fareva

    Find a price of Ganciclovir bulk with DMF, JDMF offered by Fareva

    Find a price of Haloperidol bulk with DMF, JDMF offered by Fareva

    Find a price of Levothyroxine Sodium bulk with DMF, CEP offered by Fareva

    Find a price of Methotrexate bulk with DMF, CEP offered by Fareva

    Find a price of Mianserin Hydrochloride bulk with CEP, JDMF offered by Fareva

    Find a price of Norethisterone bulk with DMF, CEP offered by Fareva

    Find a price of Trazodone Hydrochloride bulk with DMF, JDMF offered by Fareva

    Find a price of Acyclovir Sodium bulk with DMF offered by Fareva

    Find a price of Anastrozole bulk with CEP offered by Fareva

    Find a price of Baclofen bulk with DMF offered by Fareva

    Find a price of Buspirone Hydrochloride bulk with DMF offered by Fareva

    Find a price of Cevimeline Hydrochloride bulk with DMF offered by Fareva

    Find a price of Deferoxamine Mesylate bulk with DMF offered by Fareva

    Find a price of Estradiol Benzoate bulk with DMF offered by Fareva

    Find a price of Ganciclovir Sodium bulk with DMF offered by Fareva

    Find a price of Lanthanum Carbonate bulk with DMF offered by Fareva

    Find a price of Mycophenolate Mofetil bulk with DMF offered by Fareva

    Find a price of Ropivacaine Hydrochloride bulk with DMF offered by Fareva

    Find a price of Timolol Maleate bulk with DMF offered by Fareva

    Find a price of Trazodone Hydrochloride bulk with JDMF offered by Fareva

    Find a price of Altrenogest bulk offered by Fareva

    Find a price of Aripiprazole bulk offered by Fareva

    Find a price of Avibactam Sodium bulk offered by Fareva

    Find a price of Baclofen bulk offered by Fareva

    Find a price of Bempedoic Acid bulk offered by Fareva

    Find a price of Benzododecinium bromide bulk offered by Fareva

    Find a price of Bicalutamide bulk offered by Fareva

    Find a price of CAS 116539-55-0 bulk offered by Fareva

    Find a price of CAS 108436-36-8 bulk offered by Fareva

    Find a price of Clomiphene Citrate bulk offered by Fareva

    Find a price of Deracoxib bulk offered by Fareva

    Find a price of Epinastine Hydrochloride bulk offered by Fareva

    Find a price of Eplerenone bulk offered by Fareva

    Find a price of Estradiol bulk offered by Fareva

    Find a price of Estradiol Benzoate bulk offered by Fareva

    Find a price of Estradiol Cypionate bulk offered by Fareva

    Find a price of Estradiol Valerate bulk offered by Fareva

    Find a price of Firocoxib bulk offered by Fareva

    Find a price of Hydrocortisone bulk offered by Fareva

    Find a price of Levothyroxine Sodium bulk offered by Fareva

    Find a price of Losartan Potassium bulk offered by Fareva

    Find a price of Medroxyprogesterone Acetate bulk offered by Fareva

    Find a price of Methotrexate bulk offered by Fareva

    Find a price of Norethisterone Acetate bulk offered by Fareva

    Find a price of Paroxetine Mesylate bulk offered by Fareva

    Find a price of Pirenzepine bulk offered by Fareva

    Find a price of Relebactam bulk offered by Fareva

    Find a price of Relugolix bulk offered by Fareva

    Find a price of Talazoparib bulk offered by Fareva

    Find a price of Tamoxifen Citrate bulk offered by Fareva

    Find a price of Temozolomide bulk offered by Fareva

    Find a price of Tenapanor bulk offered by Fareva

    Find a price of Trenbolone Acetate bulk offered by Fareva

    Find a price of Fosaparepitant dimeglumine salt bulk offered by Fareva

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search